Brief: Design Therapeutics: On-Track To Submit Investigational New Drug Application For DT-168
24/04/2023 11:53
April 24 (Reuters) - Design Therapeutics Inc DSGN.O :
* DESIGN THERAPEUTICS INC- ON-TRACK TO SUBMIT
INVESTIGATIONAL NEW
DRUG APPLICATION FOR DT-168 IN SECOND HALF OF 2023
* DESIGN THERAPEUTICS INC- TREATMENT WITH DT-168 EYE DROPS
REDUCED
NUCLEAR FOCI AND SIGNIFICANTLY IMPROVED MIS-SPLICING IN VITRO
Source text for Eikon: ID:nGNX6mdfbJ
Further company coverage: DSGN.O
Recent news on Design Therapeutics
See all newsDesign Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Design Therapeutics Q2 net loss narrower than expected
Brief: Design Therapeutics Q2 Basic EPS USD -0.32
Design Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Design Therapeutics Announces Initiation Of Patient Dosing In Phase 1 Multiple Ascending Dose Trial Of Dt-818 For Myotonic Dystrophy Type-1